MERCK & COMPANY INC

NYSE: MRK (Merck & Company, Inc.)

Last update: 4 days ago, 7:33PM

95.55

-1.08 (-1.12%)

  • 1D -1.12%
  • 5D -2.42%
  • 1M -2.87%
  • 6M -25.22%
  • YTD -3.65%
  • 1Y -21.22%
  • 5Y 16.10%
Previous Close 96.63
Open 96.79
Volume 12,231,592
Avg. Volume (3M) 11,503,355
Market Cap 241,707,106,304
Price / Earnings (TTM) 19.99
Price / Earnings (Forward) 9.90
Price / Sales 3.85
Price / Book 5.43
52 Weeks Range
94.48 (-1%) — 134.63 (40%)
Earnings Date 4 Feb 2025
TTM Dividend Yield 3.27%
Profit Margin 19.23%
Operating Margin (TTM) 26.20%
Diluted EPS (TTM) 4.78
Quarterly Revenue Growth (YOY) 4.40%
Quarterly Earnings Growth (YOY) -33.50%
Total Debt/Equity (MRQ) 85.57%
Current Ratio (MRQ) 1.36
Operating Cash Flow (TTM) 18.26 B
Levered Free Cash Flow (TTM) 14.02 B
Return on Assets (TTM) 10.53%
Return on Equity (TTM) 28.33%

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - General (US) Mixed Mixed
Drug Manufacturers - General (Global) Mixed Mixed
Stock Merck & Company, Inc. Bearish Bearish

AIStockmoo Score

1.1
Analyst Consensus 1.0
Insider Activity NA
Price Volatility 3.5
Technical Moving Averages 2.5
Technical Oscillators -2.5
Average 1.13

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
MRK 242 B 3.27% 19.99 5.43
NVS 200 B 3.81% 17.44 4.62
LLY 706 B 0.66% 84.63 50.52
NVO 360 B 1.64% 29.72 21.28
JNJ 362 B 3.27% 25.97 4.99
ABBV 310 B 3.54% 61.03 49.89

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Sector Healthcare
Industry Drug Manufacturers - General
Investment Style Large Core
% Held by Insiders 0.06%
% Held by Institutions 79.36%
52 Weeks Range
94.48 (-1%) — 134.63 (40%)
Price Target Range
105.00 (9%) — 130.00 (36%)
High 130.00 (Guggenheim, 36.05%) Buy
Median 119.00 (24.54%)
Low 105.00 (BMO Capital, 9.89%) Hold
Average 117.00 (22.45%)
Total 5 Buy, 4 Hold
Avg. Price @ Call 99.61
Firm Date Target Price Call Price @ Call
Citigroup 28 Jan 2025 125.00 (30.82%) Buy 97.94
Morgan Stanley 21 Jan 2025 113.00 (18.26%) Hold 96.24
01 Nov 2024 123.00 (28.73%) Hold 101.88
Leerink Partners 13 Jan 2025 119.00 (24.54%) Buy 100.98
Truist Securities 08 Jan 2025 110.00 (15.12%) Hold 99.85
07 Nov 2024 130.00 (36.05%) Buy 101.17
UBS 08 Jan 2025 120.00 (25.59%) Buy 99.85
BMO Capital 20 Dec 2024 105.00 (9.89%) Hold 98.05
01 Nov 2024 136.00 (42.33%) Buy 101.88
B of A Securities 10 Dec 2024 121.00 (26.64%) Buy 101.00
Guggenheim 06 Nov 2024 130.00 (36.05%) Buy 100.73
Wells Fargo 01 Nov 2024 110.00 (15.12%) Hold 101.88
Show more

No data within this time range.

  • 3M
Date Type Details
28 Jan 2025 Announcement Merck Announces Second-Quarter 2025 Dividend and $10 Billion Share Repurchase Authorization
27 Jan 2025 CNBC Pharma is hopeful about Trump's second term — here's what to expect for drugmakers
27 Jan 2025 Announcement FDA Grants Priority Review to Merck’s Application for WELIREG® (belzutifan) for the Treatment of Patients With Advanced Pheochromocytoma and Paraganglioma (PPGL)
24 Jan 2025 Announcement Merck and Eisai Provide Update on Phase 3 LEAP-015 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination with Chemotherapy in Patients with Certain Types of Gastroesophageal Adenocarcinoma
17 Jan 2025 CNBC Ozempic is in the next round of Medicare drug price negotiations. See the full list of 15 medications
16 Jan 2025 Announcement Merck to Hold Fourth-Quarter and Full-Year 2024 Sales and Earnings Conference Call Feb. 4
08 Jan 2025 Announcement Merck’s GARDASIL® Receives Expanded Approval for Males in China
06 Jan 2025 Announcement Merck to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
20 Dec 2024 Announcement Merck Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody
19 Dec 2024 Announcement Merck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the Treatment of Adults with Virologically Suppressed HIV-1 Infection
18 Dec 2024 Announcement Merck Enters into Exclusive Global License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist
18 Dec 2024 CNBC Merck to develop weight loss pill from Chinese drugmaker in up to $2 billion licensing deal
17 Dec 2024 Announcement Merck Announces FDA Acceptance of Biologics License Application for Clesrovimab, an Investigational Long-Acting Monoclonal Antibody Designed to Protect Infants from RSV Disease During their First RSV Season
16 Dec 2024 Announcement Merck Provides Update on KeyVibe and KEYFORM Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab Fixed-Dose Combinations with Pembrolizumab
16 Dec 2024 Announcement Merck’s KEYTRUDA® (pembrolizumab) Approved in China in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy After Surgery as Adjuvant Treatment for Patients With Resectable Stage II, IIIA or IIIB NSCLC
13 Dec 2024 Announcement Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) as Treatment for Adult Patients With Certain Types of Von Hippel-Lindau Disease-Associated Tumors and for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma
11 Dec 2024 Announcement LYNPARZA® (olaparib) Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in OlympiA Phase 3 Trial
09 Dec 2024 Announcement Merck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced Epithelial Ovarian Cancer
08 Dec 2024 Announcement Merck’s Investigational Zilovertamab Vedotin in Combination With R-CHP Demonstrates Complete Response Rate of 100% at 1.75 mg/kg Dose in Phase 2 Trial of Previously Untreated Patients With Diffuse Large B-Cell Lymphoma
05 Dec 2024 Announcement Merck and Ridgeback Biotherapeutics Announce Initiation of Phase 3 Study (MOVe-NOW) Evaluating LAGEVRIO™ (molnupiravir) for the Treatment of COVID-19 in High-Risk Adults
03 Dec 2024 Announcement FDA Grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan (sac-TMT) for the Treatment of Certain Patients With Previously Treated Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer With EGFR Mutations
26 Nov 2024 Announcement Merck to Participate in the Citi 2024 Global Healthcare Conference
25 Nov 2024 Announcement Merck Announces Pivotal Phase 3 ZENITH Trial Evaluating WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint at Interim Analysis
22 Nov 2024 Announcement Merck to Participate in the 7th Annual Evercore ISI HealthCONx Conference
22 Nov 2024 Announcement Surendralal Karsanbhai Elected to Merck Board of Directors
22 Nov 2024 Announcement Merck Recommends Rejection of TRC Capital’s “Mini-Tender” Offer
22 Nov 2024 Announcement Merck’s WELIREG® (belzutifan) Approved in China for the Treatment of Adult Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors
21 Nov 2024 Announcement Merck Data at the ASH 2024 Annual Meeting Highlights Promising Hematology Pipeline With Diverse Range of Investigational Assets and Novel Modalities
19 Nov 2024 Announcement Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints
19 Nov 2024 Announcement Merck Announces First-Quarter 2025 Dividend
15 Nov 2024 Announcement Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Non-Epithelioid Malignant Pleural Mesothelioma (MPM)
14 Nov 2024 Announcement Merck to Participate in the Jefferies London Healthcare Conference
14 Nov 2024 Announcement Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd.
12 Nov 2024 Announcement KOSELUGO® (selumetinib) Showed Significant and Clinically Meaningful Improvement in Objective Response Rate Versus Placebo in Adults With Neurofibromatosis Type 1 who Have Symptomatic, Inoperable Plexiform Neurofibromas in Global Phase 3 KOMET Trial
12 Nov 2024 Announcement Merck to Present New Data From GARDASIL®9 Studies Reinforcing the Importance of Gender-Neutral HPV Vaccination in Adults Up to Age 45 at the International Papillomavirus Conference (IPVC) 2024
07 Nov 2024 CNBC Moderna posts surprise profit as Covid vaccine sales impress, cost cuts take hold 
06 Nov 2024 Announcement Merck to Participate in the UBS Global Healthcare Conference
31 Oct 2024 Announcement Merck Announces Third-Quarter 2024 Financial Results
31 Oct 2024 CNBC Merck tops earnings estimates on strong demand for Keytruda, new drugs even as HPV vaccine sales fall
28 Oct 2024 Announcement Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)
Show more
TTM Dividend Yield 3.27%
5Y Average Dividend Yield 2.96%
Payout Ratio 64.44%
Expected Next Dividend Payment Apr 2025
Ex Date Announcement Date Payment Date Details
16 Dec 2024 19 Nov 2024 08 Jan 2025 0.81 Cash
16 Sep 2024 23 Jul 2024 07 Oct 2024 0.77 Cash
17 Jun 2024 28 May 2024 08 Jul 2024 0.77 Cash
14 Mar 2024 23 Jan 2024 05 Apr 2024 0.77 Cash
14 Dec 2023 28 Nov 2023 08 Jan 2024 0.77 Cash
14 Sep 2023 25 Jul 2023 06 Oct 2023 0.73 Cash
14 Jun 2023 23 May 2023 10 Jul 2023 0.73 Cash
14 Mar 2023 24 Jan 2023 10 Apr 2023 0.73 Cash
14 Dec 2022 29 Nov 2022 09 Jan 2023 0.73 Cash
14 Sep 2022 26 Jul 2022 07 Oct 2022 0.69 Cash
14 Jun 2022 24 May 2022 08 Jul 2022 0.69 Cash
14 Mar 2022 25 Jan 2022 07 Apr 2022 0.69 Cash
14 Dec 2021 30 Nov 2021 07 Jan 2022 0.69 Cash
14 Sep 2021 27 Jul 2021 07 Oct 2021 0.65 Cash
14 Jun 2021 25 May 2021 07 Jul 2021 0.65 Cash
12 Mar 2021 26 Jan 2021 07 Apr 2021 0.65 Cash
14 Dec 2020 17 Nov 2020 08 Jan 2021 0.65 Cash
14 Sep 2020 28 Jul 2020 07 Oct 2020 0.61 Cash
12 Jun 2020 26 May 2020 07 Jul 2020 0.61 Cash
13 Mar 2020 28 Jan 2020 07 Apr 2020 0.61 Cash
13 Dec 2019 20 Nov 2019 08 Jan 2020 0.61 Cash
13 Sep 2019 24 Jul 2019 07 Oct 2019 0.55 Cash
14 Jun 2019 29 May 2019 08 Jul 2019 0.55 Cash
14 Mar 2019 30 Jan 2019 05 Apr 2019 0.55 Cash
14 Dec 2018 26 Oct 2018 08 Jan 2019 0.55 Cash
14 Sep 2018 25 Jul 2018 05 Oct 2018 0.48 Cash
14 Jun 2018 23 May 2018 09 Jul 2018 0.48 Cash
14 Mar 2018 24 Jan 2018 06 Apr 2018 0.48 Cash
14 Dec 2017 29 Nov 2017 08 Jan 2018 0.48 Cash
14 Sep 2017 26 Jul 2017 06 Oct 2017 0.47 Cash
13 Jun 2017 24 May 2017 10 Jul 2017 0.47 Cash
13 Mar 2017 28 Feb 2017 07 Apr 2017 0.47 Cash
13 Dec 2016 22 Nov 2016 09 Jan 2017 0.47 Cash
13 Sep 2016 26 Jul 2016 07 Oct 2016 0.46 Cash
13 Jun 2016 25 May 2016 08 Jul 2016 0.46 Cash
11 Mar 2016 24 Feb 2016 07 Apr 2016 0.46 Cash
11 Dec 2015 24 Nov 2015 08 Jan 2016 0.46 Cash
11 Sep 2015 22 Jul 2015 07 Oct 2015 0.45 Cash
11 Jun 2015 26 May 2015 08 Jul 2015 0.45 Cash
12 Mar 2015 24 Feb 2015 08 Apr 2015 0.45 Cash
11 Dec 2014 25 Nov 2014 08 Jan 2015 0.45 Cash
11 Sep 2014 23 Jul 2014 07 Oct 2014 0.44 Cash
12 Jun 2014 27 May 2014 08 Jul 2014 0.44 Cash
13 Mar 2014 25 Feb 2014 07 Apr 2014 0.44 Cash
12 Dec 2013 26 Nov 2013 08 Jan 2014 0.44 Cash
12 Sep 2013 23 Jul 2013 07 Oct 2013 0.43 Cash
13 Jun 2013 28 May 2013 08 Jul 2013 0.43 Cash
13 Mar 2013 26 Feb 2013 05 Apr 2013 0.43 Cash
13 Dec 2012 27 Nov 2012 08 Jan 2013 0.43 Cash
13 Sep 2012 24 Jul 2012 05 Oct 2012 0.42 Cash
13 Jun 2012 22 May 2012 09 Jul 2012 0.42 Cash
13 Mar 2012 28 Feb 2012 06 Apr 2012 0.42 Cash
13 Dec 2011 10 Nov 2011 09 Jan 2012 0.42 Cash
13 Sep 2011 26 Jul 2011 07 Oct 2011 0.38 Cash
13 Jun 2011 24 May 2011 08 Jul 2011 0.38 Cash
11 Mar 2011 22 Feb 2011 07 Apr 2011 0.38 Cash
13 Dec 2010 23 Nov 2010 07 Jan 2011 0.38 Cash
13 Sep 2010 27 Jul 2010 07 Oct 2010 0.38 Cash
11 Jun 2010 26 May 2010 08 Jul 2010 0.38 Cash
11 Mar 2010 23 Feb 2010 07 Apr 2010 0.38 Cash
11 Dec 2009 24 Nov 2009 08 Jan 2010 0.38 Cash
02 Sep 2009 28 Jul 2009 01 Oct 2009 0.38 Cash
04 Jun 2009 27 May 2009 01 Jul 2009 0.38 Cash
04 Mar 2009 24 Feb 2009 01 Apr 2009 0.38 Cash
03 Dec 2008 25 Nov 2008 02 Jan 2009 0.38 Cash
03 Sep 2008 22 Jul 2008 01 Oct 2008 0.38 Cash
04 Jun 2008 27 May 2008 01 Jul 2008 0.38 Cash
05 Mar 2008 26 Feb 2008 01 Apr 2008 0.38 Cash
05 Dec 2007 27 Nov 2007 02 Jan 2008 0.38 Cash
05 Sep 2007 24 Jul 2007 01 Oct 2007 0.38 Cash
06 Jun 2007 22 May 2007 02 Jul 2007 0.38 Cash
07 Mar 2007 27 Feb 2007 02 Apr 2007 0.38 Cash
06 Dec 2006 28 Nov 2006 02 Jan 2007 0.38 Cash
30 Aug 2006 25 Jul 2006 02 Oct 2006 0.38 Cash
31 May 2006 23 May 2006 03 Jul 2006 0.38 Cash
31 Aug 2005 26 Jul 2005 03 Oct 2005 0.38 Cash
01 Jun 2005 24 May 2005 01 Jul 2005 0.38 Cash
02 Mar 2005 22 Feb 2005 01 Apr 2005 0.38 Cash
01 Dec 2004 23 Nov 2004 03 Jan 2005 0.38 Cash
01 Sep 2004 27 Jul 2004 01 Oct 2004 0.38 Cash
02 Jun 2004 25 May 2004 01 Jul 2004 0.37 Cash
03 Mar 2004 24 Feb 2004 01 Apr 2004 0.37 Cash
03 Dec 2003 25 Nov 2003 02 Jan 2004 0.37 Cash
03 Sep 2003 22 Jul 2003 01 Oct 2003 0.37 Cash
04 Jun 2003 27 May 2003 01 Jul 2003 0.36 Cash
05 Mar 2003 25 Feb 2003 01 Apr 2003 0.36 Cash
04 Dec 2002 26 Nov 2002 02 Jan 2003 0.36 Cash
04 Sep 2002 23 Jul 2002 01 Oct 2002 0.36 Cash
05 Jun 2002 28 May 2002 01 Jul 2002 0.35 Cash
06 Mar 2002 26 Feb 2002 01 Apr 2002 0.35 Cash
05 Dec 2001 27 Nov 2001 02 Jan 2002 0.35 Cash
30 Aug 2001 24 Jul 2001 01 Oct 2001 0.35 Cash
31 May 2001 22 May 2001 02 Jul 2001 0.34 Cash
07 Mar 2001 27 Feb 2001 02 Apr 2001 0.34 Cash
06 Dec 2000 28 Nov 2000 02 Jan 2001 0.34 Cash
30 Aug 2000 25 Jul 2000 02 Oct 2000 0.34 Cash
31 May 2000 22 May 2000 03 Jul 2000 0.29 Cash
01 Mar 2000 22 Feb 2000 03 Apr 2000 0.29 Cash
01 Dec 1999 23 Nov 1999 03 Jan 2000 0.29 Cash
01 Sep 1999 27 Jul 1999 01 Oct 1999 0.29 Cash
02 Jun 1999 25 May 1999 01 Jul 1999 0.27 Cash
03 Mar 1999 23 Feb 1999 01 Apr 1999 0.27 Cash
02 Dec 1998 24 Nov 1998 04 Jan 1999 0.54 Cash
02 Sep 1998 28 Jul 1998 01 Oct 1998 0.54 Cash
03 Jun 1998 26 May 1998 01 Jul 1998 0.45 Cash
04 Mar 1998 24 Feb 1998 01 Apr 1998 0.45 Cash
03 Dec 1997 25 Nov 1997 02 Jan 1998 0.45 Cash
03 Sep 1997 22 Jul 1997 01 Oct 1997 0.45 Cash
05 Jun 1997 28 May 1997 01 Jul 1997 0.42 Cash
05 Mar 1997 25 Feb 1997 01 Apr 1997 0.42 Cash
05 Dec 1996 26 Nov 1996 02 Jan 1997 0.4 Cash
04 Sep 1996 23 Jul 1996 01 Oct 1996 0.4 Cash
06 Jun 1996 29 May 1996 01 Jul 1996 0.34 Cash
06 Mar 1996 27 Feb 1996 01 Apr 1996 0.34 Cash
06 Dec 1995 28 Nov 1995 02 Jan 1996 0.34 Cash
05 Sep 1995 25 Jul 1995 02 Oct 1995 0.34 Cash
02 Jun 1995 23 May 1995 03 Jul 1995 0.3 Cash
Show more

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2025 0.810 1 0.85
2024 3.08 4 3.10
2023 2.92 4 2.68
2022 2.76 4 2.49
2021 2.60 4 3.39
2020 2.44 4 3.13
2019 2.20 4 2.54
2018 1.92 4 2.63
2017 1.88 4 3.50
2016 1.84 4 3.28
2015 1.80 4 3.57
2014 1.76 4 3.25
2013 1.72 4 3.60
2012 1.68 4 4.30
2011 1.52 4 4.23
2010 1.52 4 4.42
2009 1.52 4 4.36
2008 1.52 4 5.24
2007 1.52 4 2.74
2006 0.760 2 1.83
2005 1.52 4 5.01
2004 1.49 4 4.86
2003 1.45 4 3.29
2002 1.41 4 2.61
2001 1.37 4 2.44
2000 1.21 4 1.35
1999 1.37 4 2.14
1998 1.89 4 2.69
1997 1.69 4 3.34
1996 1.42 4 3.74
1995 0.640 2 2.04
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria